Intelligencia AI, a provider of AI-powered solutions that support data-driven decision-making in drug development, announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,948,667 on April 2, 2024.
The patent titled,”System and Interfaces for Processing and Interacting With Clinical Data,” pertains to the company’s novel techniques for training and leveraging a machine learning (ML) model to predict the likelihood of FDA approval for a particular drug.
The patent includes the company’s flagship solution, Intelligencia Portfolio Optimizer, and its underlying methodology. The SaaS platform delivers on-demand access to AI-powered insights based on best-in-class, proprietary data and proven AI algorithms. The on-demand solution enables customers to objectively assess the probability of technical and regulatory success (PTRS) and phase transition probabilities. Equipped with this knowledge, portfolio, business development, corporate development and research & development leaders can confidently make more informed and efficient asset, portfolio and licensing decisions.
One notable element covered in the patent is that if one or more of the parameters for the clinical trial under investigation have been modified, the patented approach and technology adjust the assessments of the probability of success and phase transitions, upholding data integrity and high-accuracy standards.
The predictive performance of Intelligencia AI algorithms in forecasting FDA approvals for Phase 2 oncology programs boasts a prospectively validated accuracy of 83%*, and 90% when measured retrospectively.
CEO and co-founder Dimitrios Skaltsas shared, “We’re incredibly excited and proud of this recognition by USPTO and our impact in the pharma space. This patent has been a long time in the making and marks a significant milestone in signifying Intelligencia AI as a pioneer and a leader in applying AI to de-risk clinical development and enhance decision-making through accurate, AI-driven probability of success (PoS).”
SOURCE: GlobeNewswire
